Head-To-Head Contrast: Septerna (NASDAQ:SEPN) & XTL Biopharmaceuticals (NASDAQ:XTLB)

Septerna (NASDAQ:SEPN) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares Septerna and XTL Biopharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$96.27 million	21.54	-$48.88 million	($1.29)	-34.43
XTL Biopharmaceuticals	N/A	N/A	-$6.97 million	($0.64)	-2.77

XTL Biopharmaceuticals has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than XTL Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Septerna has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Profitability

This table compares Septerna and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Septerna	-61.29%	-14.98%	-10.03%
XTL Biopharmaceuticals	N/A	N/A	N/A

Institutional & Insider Ownership

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Septerna and XTL Biopharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1	1	8	1	2.82
XTL Biopharmaceuticals	1	0	0	0	1.00

Septerna currently has a consensus target price of $56.44, suggesting a potential upside of 27.07%. Given Septerna’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Septerna is more favorable than XTL Biopharmaceuticals.

Summary

XTL Biopharmaceuticals beats Septerna on 8 of the 14 factors compared between the two stocks.

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. is an Israeli clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. The company’s work is centered on treatments intended to regulate abnormal immune-system activity rather than broadly suppressing immune function. XTL’s principal development program has been hCDR1, also known as rigerimod, a synthetic peptide designed to modulate immune responses associated with systemic lupus erythematosus, or lupus. The candidate has been evaluated in clinical development for autoimmune indications, although its regulatory and commercial status may change as the company advances or revises its pipeline.